文献速递特殊人群用药治疗药物监测与药物基因组学

抗体药物偶联物在非小细胞肺癌中的应用

Antibody-Drug Conjugates in Non-small Cell Lung Cancer.
PubMed 文献 · Drugs · 2026-05-18

本文综述了抗体药物偶联物(ADC)在非小细胞肺癌(NSCLC)中的现有数据,涵盖经治晚期驱动基因阳性与阴性肿瘤的II/III期试验,并探讨一线及早期阶段的扩展研究。强调需结合临床特征、药物基因组学与最佳治疗顺序优化患者选择,以最大化获益并限制毒性,同时需理解耐药机制并开发验证预测性生物标志物。

要点

  • ADC由单克隆抗体、连接子和细胞毒性载荷组成,可选择性递送细胞毒药物至肿瘤细胞。
  • ADC已在经治晚期NSCLC(驱动基因阳性及阴性)的II/III期试验中评估。
  • 优化患者选择需整合临床特征、药物基因组学及治疗顺序,并关注耐药机制与生物标志物。

核心结论

  • ADC在经治晚期NSCLC中已有II/III期试验数据,并正扩展至一线及早期阶段。
  • 改善患者选择需结合临床特征、药物基因组学和最佳治疗顺序,以最大化获益并限制毒性。
  • 理解耐药机制及开发验证预测性生物标志物对指导临床实践至关重要。

研究设计与样本

  • 叙述性综述,总结ADC治疗NSCLC的现有数据。

主要发现

  • ADC通过抗体结合肿瘤抗原后内化、降解并释放载荷发挥抗肿瘤活性。
  • ADC已在经治晚期NSCLC的II/III期试验中评估,涵盖驱动基因阳性和阴性肿瘤。
  • 正在进行的临床试验将ADC扩展至晚期一线及更早期疾病阶段。

临床怎么用

  • 临床选择ADC治疗NSCLC患者时,应综合考虑临床特征、药物基因组学及最佳治疗顺序。
  • 需关注耐药机制并探索预测性生物标志物以指导ADC的临床应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antibody-drug conjugates (ADCs) are complex molecules composed of a monoclonal antibody, a linker and a cytotoxic payload. Their design enables the selective delivery of cytotoxic agents to tumoral cells through antibody binding to a tumor-expressed antigen, followed by internalization, intracellular degradation and payload release, ultimately enabling the cytotoxic drug to exert its antitumor activity. ADCs have been evaluated in phase II and III trials in previously treated advanced non-small cell lung cancer (NSCLC), both in oncogene-addicted and in non-oncogene-addicted tumors, addressing resistance to standard therapies. Ongoing clinical trials are now expanding their use both in the first-line setting for advanced disease and in earlier disease stages. This narrative review summarizes the currently available data for ADC treatment in NSCLC, highlighting the need for improved patient selection to maximize benefit while limiting toxicity, incorporating clinical characteristics, pharmacogenomics and optimal treatment sequencing in the equation. Moreover, the understanding of resistance mechanisms and the development and validation of predictive biomarkers will be of utmost relevance to inform clinical practice.

来源:Drugs,查看原文。版权归原作者所有。

引用

  1. Zullo L, Bortolot M, Ogliari FR, et al. Antibody-Drug Conjugates in Non-small Cell Lung Cancer. Drugs. 2026. PMID: 42151668. doi:10.1007/s40265-026-02331-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。